Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.39 |
| ▸ | MTOR | P42345 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344806 | 0.84 | NPC1 (0.47) | MTORP2RX7ADORA1 | |
| SCHEMBL25343317 | 0.84 | MTOR (0.46) | MTORP2RX7 | |
| SCHEMBL30745937 | 0.82 | SMYD3 (0.44) | P2RY12MTORPTGDR2P2RX7PPARG | |
| SCHEMBL25342685 | 0.80 | P2RX7 (0.40) | MTOREGFRP2RX7 | |
| SCHEMBL30745930 | 0.78 | OPRD1 (0.38) | P2RY12PTGDR2EGFRADORA3SMYD3 | |
| SCHEMBL25342589 | 0.77 | ADORA1 (0.45) | ADORA3ADORA1 | |
| SCHEMBL25340780 | 0.77 | MTOR (0.47) | MTOR | |
| SCHEMBL30613801 | 0.76 | P2RY12 (0.42) | P2RY12ADORA3ADORA1 | |
| SCHEMBL25343381 | 0.74 | PARP1 (0.42) | MTORP2RX7 | |
| SCHEMBL25343007 | 0.73 | MTOR (0.37) | MTOREGFRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516064-B2 | Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD | SpringWorks Therapeutics Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | P2RY12 4428/4885MTOR 574/4885PTGDR2 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.